Formoterol en polvo seco, dos veces al día versus salbutamol aerosol, cuatro veces al día, en pacientes con asma estable

Revista Alergia Mexico

Volumn 46, Issue 5, 1999, Pages 130-135

  Rico Méndez, Favio Gerardo ^a,f   Ochoa, G ^a   Rocio Chapela, M ^b   Diaz, Manuel ^c   Cohen, V ^d   Ibarra, J ^d   Tellez E ^e  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^c HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^d Depto de Invest Novartis   (Mexico)

^e CENTRO MÉDICO NACIONAL 20 DE NOVIEMBRE   (Mexico)

^f Delegación Azcapoualco   (Mexico)

Author keywords

Bronchial asthma; Formoterol; Salbutamol

Indexed keywords

FORMOTEROL; SALBUTAMOL;

ADOLESCENT; ADULT; AEROSOL; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG FORMULATION; DRY POWDER; DYSPNEA; FEMALE; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NERVOUSNESS; RANDOMIZED CONTROLLED TRIAL; TACHYCARDIA;

EID: 6944257050     PISSN: 00025151     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Global Initiative for Asthma NHLBI/WHO Workshop report. National Institutes of Health. National Heart, Lung, and Blood Institute. 1995. Pub No. 95-3659.
2. Barnes PJ, Pederson S. Efficacy and safety of inhaled corticosteroids in asthma. Am.Rev.Respir.Dis. 1993; 14S:S1-S26,
3. Dahl R., Lundback E., Malo JI., A. Dose ranging study of fluticonasole propionate in adult patients with moderate asthma. Chest 1993; 104:1352-1358.
4. Haahtela T., Jarvinen M., Kava T. Comparison of a beta 2 agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N. Engl. J. Med. 1991; 325:338-392.
5. Papi A., Braccioni f., camero G., Fabbri L. Evidence of oral therapeutic interventions in asthma. Eur.Respir.Rev. 1998: 58:317-321.
6. National asthma Education an Prevention Program. Espert Panel Report 2: Guidelines from the Diagnosis and management of Asthma. US Dept. 7, Health & Human Services. NIH 1997: 97-405IA.
7. Global Initiative for asthma. Global Strategy for Asthma Management and Prevetion. WHO/NHLBI Workshop Report. Bethestda MD, National Institutes of Health, Publ No. 95-3659: 1995; 1-48.
8. British Thoracic Society: Guidelines on the management of Asthma. Thorax. 1993; 48 (suppl) S1-S24.
9. Dougbjerg P., Nielsen KG, Skov M., Bisggard H. Duration of action of formoterol and salbutamol dry power inhalation in prevetion of excercise - induced asthma in childre. Acta Paediatr. 1996; 85:684-687.
10. Löfdahl CG., Chung KF. Long acting B2 adrenoceptor agonists: a new perspective in the treatment of asthma. Eur. Respir J. 1994; 4:218-226.
11. Wallin A., Sandtrom T., Rosenhall L., Melander B. Time course and duration of bronchodilation with formoterol dry powder in patients with stable asthma. Thorax 1993, 48:611-614.
12. Maesen FP, Smeets JJ, Costung MA, Zweers PG, Pfeil Jp, Onset of action of formoterol by dry powder inhaler: objetive and subjetive measures. Dr. J Clin Pract. 1995: 49:294-296.
13. Linden A., Rabe KF, Löfdahl CG. Phannacological basis for duration of effect: formoterol and salmeterol versos short acting B2-adrenoceptor agonist. Lung 1996; 174:1-22.
14. Buist S. Development of evidence based guidelines for inhaled therapeutic interventions in asthma. Eur.Respir.Rev. 1998; 58:322-323.
15. Sears MR, Taylo DR, Print CG. Regular inhaled beta - agonist treatment in bronchial asthma. Lancet 1990; 336:1391-1396.
16. Drazen JM, Israel E., Boushey HA. Comparison of regularly scheduled with as-needed use of salbutamol in mild asthma. N. Engl J. Med. 1996; 335:841-847.
17. Wallind A, Sandström T, Rosenhall L, Melander B. Time course and duration of broncodilation with formoterol dry in patients with stable asthma. Thorax. 1993; 48:611-614.
18. Steffensen I, Faurshow P, Riska H, Rostrup J, Wegner T. Inhaled formoterol dry power in the treatment of patients reversibles obstructive airways disease. A 3 month placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12 -month trial with formoterol. Allerey 1995; 50:657-663.
19. Pauwels RA, Löfdhal Cg, Postma DS, Tattersfield AE, O'Byrne P, Barnes PH y Cols. Effect in inhaled formoterol and budesonide on exacerbations of asthma. N. Engl J. Med.1997; 337:1405-1411.
20. Clauzel AM, Molimard M, Le Gros V, Lepere E, Fevre N, Michel FB. Use of formoterol dry powder administered for three months via a single - dose inhaler in 1380 asthmatic patient. Invest Allergol Clin. Immunol. 1998; 8:265-270.